Stay updated on Nivolumab & Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab & Ipilimumab in Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T14:41:58.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    An updated site revision label (Revision: v3.4.2) was added, and the previous funding notice and Revision: v3.4.1 deletion were removed; these are administrative changes unrelated to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T01:22:24.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide notice about government funding was added, and the site version updated to v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T00:43:51.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Adds a Show glossary option and introduces updated labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', plus a new 'Revision: v3.4.0'. The previous wording and version label ('Last Update Submitted that met QC Criteria', 'No FEAR Act data', 'Revision: v3.3.4') were removed.
    Difference
    0.2%
    Check dated 2026-01-28T00:39:31.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.4, replacing Revision: v3.3.3.
    Difference
    0.1%
    Check dated 2026-01-14T01:48:54.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A centralized 'Locations' section was added listing Florida, Indiana, Massachusetts, Pennsylvania, Tennessee, and Virginia, replacing the previous separate location subsections. The footer link 'HHS Vulnerability Disclosure' was removed and the page revision updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-23T17:15:20.000Z thumbnail image

Stay in the know with updates to Nivolumab & Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.